Monitoring of biochemical parameters and coagulation tests in children with epilepsy treated with levetiracetam monotherapy
- 71 Downloads
Levetiracetam (LEV)-associated hyponatremia, hypokalemia, and hypomagnesemia and increase in serum albumin have been described in adult patients [2, 5, 7]. Furthermore, in well-controlled studies of add-on levetiracetam therapy for epilepsy, the incidence of coagulation and bleeding disorders was slightly higher in the LEV group than that in the placebo group (2.8% vs 1.7%) . Whether young age may have a protective role in the prevention of the above LEV-associated disorders has not been studied. The objective of this study was to prospectively investigate the long-term effect of LEV monotherapy in all the above parameters in children with epilepsy.
The study population consisted of 28 ambulatory children (16 females, mean age 6.5 ± 4.4 years, range 1–15 years) that were treated for new-onset epilepsy with LEV monotherapy. Twenty-three children suffered from focal epilepsy and 5 from generalized epilepsy. An informed parental consent was obtained and the study was...
Compliance with ethical standards
An informed parental consent was obtained and the study was approved by the Institutional Review Board of “Attikon” University Hospital.
Conflict of interest
The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper.
- 1.Baier H, Bosiger J, Bombeli T, Kramer G (2003) Levetiracetam might induce or aggravated von Willebrand disease: a case report [abstract]. Epilepsia 44(suppl 8):118Google Scholar
- 4.Eccher M, Swartz BE, Werz MA, Robinson S, Maciunas RJ (2002) Possible relation of levetiracetam therapy to hemorrhagic complications in epilepsy surgery [abstract]. Epilepsia 43(suppl 7):206Google Scholar